Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8213152 | International Journal of Radiation Oncology*Biology*Physics | 2017 | 8 Pages |
Abstract
According to this protocol, the SFL rate was clearly higher than the critical value, with acceptable levels of toxicity. The use of cetuximab added to radiation therapy in patients with stage III and IVA laryngeal cancer who respond to TPF could improve functional larynx preservation. A phase 3 trial is warranted.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Ricard MD, PhD, Jose A. MD, Alicia MD, Miguel MD, Juan J. MD, PhD, Javier MD, Julio MD, Joaquina MD, Jose R. MD, Belen MD, Silvia MD, Manel MD, PhD, Miren MD, Beatriz MD, Elvira MD, Esther MD, Jordi MD, Angles MD, Juan J. MD, PhD,